<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Harnessing nitric oxide for preventing, limiting and treating the severe" exact="pulmonary" post="consequences of COVID-19 AdusumilliNagasai C.aZhangDavidbFriedmanJoel M.joel.friedman@einsteinmed.orgbâˆ—âˆ—FriedmanAdam J.ajfriedman@mfa.gwu.eduaâˆ—[a], [b], âˆ—Corresponding"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="quickly become a daunting challenge to global health. In the" exact="absence of" post="targeted therapy and a reported 5.5% case fatality rate"/>
 <result pre="features, pathology and homology to better understood pathogens suggest that" exact="uncontrolled" post="inflammation and a cytokine storm likely drive COVID-19's unrelenting"/>
 <result pre="uncontrolled inflammation and a cytokine storm likely drive COVID-19's unrelenting" exact="disease" post="process. Interventions that are protective against acute lung injury"/>
 <result pre="drive COVID-19's unrelenting disease process. Interventions that are protective against" exact="acute" post="lung injury and ARDS can play a critical role"/>
 <result pre="is an antimicrobial and anti-inflammatory molecule with key roles in" exact="pulmonary" post="vascular function in the context of viral infections and"/>
 <result pre="an antimicrobial and anti-inflammatory molecule with key roles in pulmonary" exact="vascular" post="function in the context of viral infections and other"/>
 <result pre="key roles in pulmonary vascular function in the context of" exact="viral" post="infections and other pulmonary disease states. This article reviews"/>
 <result pre="roles in pulmonary vascular function in the context of viral" exact="infections" post="and other pulmonary disease states. This article reviews the"/>
 <result pre="vascular function in the context of viral infections and other" exact="pulmonary" post="disease states. This article reviews the rationale for exogenous"/>
 <result pre="function in the context of viral infections and other pulmonary" exact="disease" post="states. This article reviews the rationale for exogenous nitric"/>
 <result pre="when they cross the species barrier, coronaviruses have been highly" exact="infectious" post="and lethal to humans in the severe acute respiratory"/>
 <result pre="been highly infectious and lethal to humans in the severe" exact="acute" post="respiratory syndrome (SARS) outbreak in 2002, Middle East respiratory"/>
 <result pre="highly infectious and lethal to humans in the severe acute" exact="respiratory" post="syndrome (SARS) outbreak in 2002, Middle East respiratory syndrome"/>
 <result pre="infectious and lethal to humans in the severe acute respiratory" exact="syndrome" post="(SARS) outbreak in 2002, Middle East respiratory syndrome (MERS)"/>
 <result pre="severe acute respiratory syndrome (SARS) outbreak in 2002, Middle East" exact="respiratory" post="syndrome (MERS) outbreak in 2012, and in the current"/>
 <result pre="acute respiratory syndrome (SARS) outbreak in 2002, Middle East respiratory" exact="syndrome" post="(MERS) outbreak in 2012, and in the current coronavirus"/>
 <result pre="syndrome (MERS) outbreak in 2012, and in the current coronavirus" exact="disease" post="2019 (COVID-19) pandemic [2,3]. Up to the submission date,"/>
 <result pre="[4]. To date no registered treatment or vaccine for the" exact="disease" post="exists. Various general treatments, from nutritional interventions to antivirals"/>
 <result pre="increase morbidity and mortality in severely ill patients [6]. The" exact="absence of" post="a specific treatment and the high mortality rate dictate"/>
 <result pre="the lungs, preventing the onset and development of COVID-19 associated" exact="acute" post="respiratory distress syndrome (ARDS) and treating ARDS. 2 Pathophysiology"/>
 <result pre="lungs, preventing the onset and development of COVID-19 associated acute" exact="respiratory" post="distress syndrome (ARDS) and treating ARDS. 2 Pathophysiology of"/>
 <result pre="the onset and development of COVID-19 associated acute respiratory distress" exact="syndrome" post="(ARDS) and treating ARDS. 2 Pathophysiology of COVID-19 Symptomatic"/>
 <result pre="and myalgias. The mortality stems from rapid, severe progression to" exact="acute" post="lung injury (ALI), ARDS, respiratory failure, sepsis or cardiac"/>
 <result pre="from rapid, severe progression to acute lung injury (ALI), ARDS," exact="respiratory" post="failure, sepsis or cardiac arrest. Pathological reports from postmortem"/>
 <result pre="to acute lung injury (ALI), ARDS, respiratory failure, sepsis or" exact="cardiac arrest." post="Pathological reports from postmortem assessment describe bilateral diffuse alveolar"/>
 <result pre="sepsis or cardiac arrest. Pathological reports from postmortem assessment describe" exact="bilateral" post="diffuse alveolar damage with edema, pneumocyte desquamation, hyaline membrane"/>
 <result pre="or cardiac arrest. Pathological reports from postmortem assessment describe bilateral" exact="diffuse" post="alveolar damage with edema, pneumocyte desquamation, hyaline membrane formation"/>
 <result pre="damage with edema, pneumocyte desquamation, hyaline membrane formation and massive" exact="pulmonary embolism" post="[7,8]. These pathological features resemble the pneumonia seen with"/>
 <result pre="and massive pulmonary embolism [7,8]. These pathological features resemble the" exact="pneumonia" post="seen with SARS and MERS [9,10]. The overall nucleotide"/>
 <result pre="established literature about the pathophysiology of SARS-CoV-1. In addition to" exact="viral" post="overload, animal models have illustrated apoptosis of epithelium and"/>
 <result pre="inflammatory and immune responses leading to a cytokine storm. Subsequent" exact="vascular" post="permeability and abnormal T-cell and macrophage responses induce ALI"/>
 <result pre="to prevent the rapid progression to the ARDS and fulminant" exact="systemic" post="organ failure that are driving mortality with COVID-19. Factors"/>
 <result pre="(RBC) damage. A normal NO/ROS balance is crucial for normal" exact="vascular" post="function. NO is an endothelium-derived relaxing factor that plays"/>
 <result pre="is an endothelium-derived relaxing factor that plays key roles in" exact="vascular" post="signaling, regulation of blood flow and host defense [15]."/>
 <result pre="as host defense and are induced during stress, such as" exact="viral infection" post="[16]. An excess of ROS, such as in viral"/>
 <result pre="host defense and are induced during stress, such as viral" exact="infection" post="[16]. An excess of ROS, such as in viral"/>
 <result pre="viral infection [16]. An excess of ROS, such as in" exact="viral" post="overload, activates M1 macrophages, recruits neutrophils and enhances production"/>
 <result pre="cytokines, such as interleukin (IL)-2, IL-6, IL-8, interferon (IFN)-Î±/Î² and" exact="tumor" post="necrosis factor (TNF)- Î±, that neutralize invading organisms but"/>
 <result pre="(TNF)- Î±, that neutralize invading organisms but also compound the" exact="vascular" post="damage [18]. Furthermore, inflammation-induced platelet activation, which can be"/>
 <result pre="lead to increased coagulation, an important reported consequence of the" exact="disease" post="[19]. Lippi and Mattiuzzi recently reported evidence of SARS-CoV-2"/>
 <result pre="platelets [21,22]. Enhanced clotting and sluggish blood flow result in" exact="systemic" post="hypoxia in oxygen-sensitive organs such as the kidneys [23]."/>
 <result pre="[21,22]. Enhanced clotting and sluggish blood flow result in systemic" exact="hypoxia" post="in oxygen-sensitive organs such as the kidneys [23]. Repolarization"/>
 <result pre="the novel virus's pathophysiology [11,[24], [25], [26]]. The genes for" exact="viral" post="entry and for ACE2 expression are highly enriched in"/>
 <result pre="significant role for ACE2 in infectivity and the course of" exact="infection" post="[27]. ACE and ACE2 serve opposing physiological functions. After"/>
 <result pre="I to angiotensin II, ATII binds its receptor to constrict" exact="blood vessels." post="ACE2 inactivates ATII and generates angiotensin 1-7 and promotes"/>
 <result pre="and contributes to unchecked downstream effects of ACE, including increased" exact="vascular" post="permeability and decreased anti-inflammatory mediators such as NO. This"/>
 <result pre="gas produced from arginine in mammalian cells by three enzymes:" exact="neuronal" post="(nNOS), endothelial (eNOS) and inducible nitric oxide synthase (iNOS)"/>
 <result pre="(iNOS) [34]. In host cells iNOS is commonly elevated during" exact="infection" post="by viruses, and in SARS-CoV-1 infection, NO inhibits viral"/>
 <result pre="during infection by viruses, and in SARS-CoV-1 infection, NO inhibits" exact="viral" post="replication by cytotoxic reactions through intermediates such as peroxynitrite"/>
 <result pre="NO synthesis, the molecule is additionally well-placed to respond to" exact="viral" post="attack. As discussed above, NO plays key roles in"/>
 <result pre="As discussed above, NO plays key roles in maintaining normal" exact="vascular" post="function and regulating inflammatory cascades that contribute to ALI"/>
 <result pre="ARDS is already present, NO improves arterial oxygenation and blunts" exact="pulmonary" post="hypertension by dilating pulmonary vessels in ventilated lung parenchyma"/>
 <result pre="is already present, NO improves arterial oxygenation and blunts pulmonary" exact="hypertension" post="by dilating pulmonary vessels in ventilated lung parenchyma [37]."/>
 <result pre="NO improves arterial oxygenation and blunts pulmonary hypertension by dilating" exact="pulmonary" post="vessels in ventilated lung parenchyma [37]. These supportive changes"/>
 <result pre="to decreased ventilator support, improved density of lung infiltrates on" exact="chest" post="radiography and persistence of therapeutic benefits after discontinuation of"/>
 <result pre="[38]. The vulnerable populations in the current pandemic may have" exact="lower" post="levels of endogenously produced NO. NO generated from eNOS"/>
 <result pre="generated from eNOS drops off with age, and patients with" exact="chronic" post="vascular inflammation, such as in type 2 diabetes, metabolic"/>
 <result pre="from eNOS drops off with age, and patients with chronic" exact="vascular" post="inflammation, such as in type 2 diabetes, metabolic syndrome,"/>
 <result pre="age, and patients with chronic vascular inflammation, such as in" exact="type 2" post="diabetes, metabolic syndrome, chronic obstructive pulmonary disease, obesity, autoimmune"/>
 <result pre="with chronic vascular inflammation, such as in type 2 diabetes," exact="metabolic syndrome," post="chronic obstructive pulmonary disease, obesity, autoimmune disorders and hemoglobinopathies,"/>
 <result pre="vascular inflammation, such as in type 2 diabetes, metabolic syndrome," exact="chronic" post="obstructive pulmonary disease, obesity, autoimmune disorders and hemoglobinopathies, may"/>
 <result pre="such as in type 2 diabetes, metabolic syndrome, chronic obstructive" exact="pulmonary" post="disease, obesity, autoimmune disorders and hemoglobinopathies, may produce less"/>
 <result pre="type 2 diabetes, metabolic syndrome, chronic obstructive pulmonary disease, obesity," exact="autoimmune" post="disorders and hemoglobinopathies, may produce less eNOS [34,39,40]. Additionally,"/>
 <result pre="relative to ACE2 activity may be elevated in patients with" exact="chronic" post="vascular inflammation [41,42]. Older patients with vascular stressors from"/>
 <result pre="to ACE2 activity may be elevated in patients with chronic" exact="vascular" post="inflammation [41,42]. Older patients with vascular stressors from underlying"/>
 <result pre="in patients with chronic vascular inflammation [41,42]. Older patients with" exact="vascular" post="stressors from underlying chronic medical conditions may exhibit inadequate"/>
 <result pre="vascular inflammation [41,42]. Older patients with vascular stressors from underlying" exact="chronic" post="medical conditions may exhibit inadequate vascular NO levels, increasing"/>
 <result pre="vascular stressors from underlying chronic medical conditions may exhibit inadequate" exact="vascular" post="NO levels, increasing their vulnerability to H/R and I/R"/>
 <result pre="targeted patient populations may be a treatment that can reduce" exact="viral" post="load in the lungs, prevent the chain of events"/>
 <result pre="existing literature shows mixed efficacy when expanding outside the SARS-CoV-1" exact="disease" post="model [38,44]. Systematic review and meta-analysis of randomized controlled"/>
 <result pre="releasing nanoparticles (NO-nps) demonstrate potential in limiting inflammatory cascades and" exact="ischemia" post="reperfusion injury [50,51]. We propose that delivering modest, persistent"/>
 <result pre="of iNO or RSNO at the early stages of COVID-19" exact="infection" post="might limit the progression toward ARDS and fulminant systemic"/>
 <result pre="COVID-19 infection might limit the progression toward ARDS and fulminant" exact="systemic" post="failure, particularly in vulnerable patients who may have decreased"/>
 <result pre="to increased age or comorbid conditions. This approach should decrease" exact="viral" post="replication, downregulate ACE, prevent the onset of any hypoxia-reoxygenation/ischemia"/>
 <result pre="debris, limit lipid peroxidation and concomitant cell damage, reduce detrimental" exact="vascular" post="permeability and maintain proper blood flow. NO is one"/>
 <result pre="firm currently uses INOpulse for other cardiopulmonary indications, such as" exact="pulmonary" post="hypertension associated with pulmonary fibrosis. Portable and designed to"/>
 <result pre="currently uses INOpulse for other cardiopulmonary indications, such as pulmonary" exact="hypertension" post="associated with pulmonary fibrosis. Portable and designed to deliver"/>
 <result pre="for other cardiopulmonary indications, such as pulmonary hypertension associated with" exact="pulmonary" post="fibrosis. Portable and designed to deliver NO in outpatient"/>
 <result pre="treat patients with COVID-19 at home [54]. Currently used for" exact="persistent pulmonary hypertension of the newborn," post="GENOSYL is a tankless device that provides even more"/>
 <result pre="patients with COVID-19 at home [54]. Currently used for persistent" exact="pulmonary" post="hypertension of the newborn, GENOSYL is a tankless device"/>
 <result pre="with COVID-19 at home [54]. Currently used for persistent pulmonary" exact="hypertension" post="of the newborn, GENOSYL is a tankless device that"/>
 <result pre="describe solely outpatient management of a patient with concomitant idiopathic" exact="pulmonary" post="arterial hypertension and COVID-19 disease, reporting symptomatic improvement with"/>
 <result pre="solely outpatient management of a patient with concomitant idiopathic pulmonary" exact="arterial hypertension" post="and COVID-19 disease, reporting symptomatic improvement with GENOSYL DSÂ®"/>
 <result pre="outpatient management of a patient with concomitant idiopathic pulmonary arterial" exact="hypertension" post="and COVID-19 disease, reporting symptomatic improvement with GENOSYL DSÂ®"/>
 <result pre="with concomitant idiopathic pulmonary arterial hypertension and COVID-19 disease, reporting" exact="symptomatic" post="improvement with GENOSYL DSÂ® with no urgent care, emergency"/>
 <result pre="to the evidence of their efficacy in various models of" exact="cardiovascular" post="dysfunction, donor compounds should absolutely be explored for early"/>
 <result pre="be particularly conducive in targeting the virus's pathology in the" exact="respiratory" post="tract before widespread systemic manifestations. Successful results would be"/>
 <result pre="targeting the virus's pathology in the respiratory tract before widespread" exact="systemic" post="manifestations. Successful results would be instrumental in improving patient"/>
 <result pre="pressing need for effective agents that can slow down the" exact="disease" post="in their bodies and in their communities. While the"/>
 <result pre="of severe illness. Nitric oxide has demonstrated promise in similar" exact="respiratory" post="disease models in modulating the prominent inflammation, and the"/>
 <result pre="severe illness. Nitric oxide has demonstrated promise in similar respiratory" exact="disease" post="models in modulating the prominent inflammation, and the early"/>
 <result pre="geared toward the right population at the optimal stage of" exact="infection" post="may be an accessible, compelling option for patients. If"/>
 <result pre="Am. Med. Assoc.32320202020522059Published online 7XuZ.ShiL.WangY.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir. Med.842020420422[published correction appears in Lancet"/>
 <result pre="Med. Assoc.32320202020522059Published online 7XuZ.ShiL.WangY.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir. Med.842020420422[published correction appears in Lancet Respir"/>
 <result pre="in Lancet Respir Med. 2020 Feb 25;:]32085846 8WichmannD.SperhakeJ.P.LÃ¼tgehetmannM.Autopsy findings and" exact="venous thromboembolism" post="in patients with COVID-19 [published online ahead of print,"/>
 <result pre="online ahead of print, 2020 May 6]Ann. Intern. Med.2020M20M200310.7326/M20-2003 9BradleyB.T.BryanA.Emerging" exact="respiratory" post="infections: the infectious disease pathology of SARS, MERS, pandemic"/>
 <result pre="print, 2020 May 6]Ann. Intern. Med.2020M20M200310.7326/M20-2003 9BradleyB.T.BryanA.Emerging respiratory infections: the" exact="infectious disease" post="pathology of SARS, MERS, pandemic influenza, and LegionellaSemin. Diagn."/>
 <result pre="2020 May 6]Ann. Intern. Med.2020M20M200310.7326/M20-2003 9BradleyB.T.BryanA.Emerging respiratory infections: the infectious" exact="disease" post="pathology of SARS, MERS, pandemic influenza, and LegionellaSemin. Diagn."/>
 <result pre="10ToK.TongJ.H.ChanP.K.Tissue and cellular tropism of the coronavirus associated with severe" exact="acute" post="respiratory syndrome: an inâ€�situ hybridization study of fatal casesJ."/>
 <result pre="and cellular tropism of the coronavirus associated with severe acute" exact="respiratory" post="syndrome: an inâ€�situ hybridization study of fatal casesJ. Pathol.20222004157â€�16314743497"/>
 <result pre="and Pathobiology2009AcademicCambridge, MA 16AkaikeT.MaedaH.Nitric oxide and virus infectionImmunology101200030030811106932 17TejeroJ.ShivaS.GladwinM.T.Sources of" exact="vascular" post="nitric oxide and reactive oxygen species and their regulationPhysiol."/>
 <result pre="and their regulationPhysiol. Rev.9912019 Jan 131137930379623 18CheungC.Y.PoonL.NgI.Cytokine responses in severe" exact="acute" post="respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to"/>
 <result pre="their regulationPhysiol. Rev.9912019 Jan 131137930379623 18CheungC.Y.PoonL.NgI.Cytokine responses in severe acute" exact="respiratory" post="syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesisJ."/>
 <result pre="regulationPhysiol. Rev.9912019 Jan 131137930379623 18CheungC.Y.PoonL.NgI.Cytokine responses in severe acute respiratory" exact="syndrome" post="coronavirus-infected macrophages in vitro: possible relevance to pathogenesisJ. Virol.75200578197826"/>
 <result pre="20LippiG.MattiuzziC.Hemoglobin value may be decreased in patients with severe coronavirus" exact="disease" post="2019Hematol. Transfus. Cell Ther.422202011611732284281 21ZhangR.HessD.T.QianZ.Hemoglobin Î²Cys93 is essential for"/>
 <result pre="disease 2019Hematol. Transfus. Cell Ther.422202011611732284281 21ZhangR.HessD.T.QianZ.Hemoglobin Î²Cys93 is essential for" exact="cardiovascular" post="function and integrated response to hypoxiaProc. Natl. Acad. Sci."/>
 <result pre="U.S.A.1122020156425643025810253 22CabralesP.Examining and mitigating acellular hemoglobin vasoactivityAntioxidants Redox Signal.1817201323292341 23ChengY.LuoR.WangK.Kidney" exact="disease" post="is associated with in-hospital death of patients with COVID-19Kidney"/>
 <result pre="30AntonelliM.AzoulayE.BontenM.Year in review in Intensive Care Medicine, 2008: II. Experimental," exact="acute" post="respiratory failure and ARDS, mechanical ventilation and endotracheal intubationIntensive"/>
 <result pre="in review in Intensive Care Medicine, 2008: II. Experimental, acute" exact="respiratory" post="failure and ARDS, mechanical ventilation and endotracheal intubationIntensive Care"/>
 <result pre="and ARDS, mechanical ventilation and endotracheal intubationIntensive Care Med.352200921523119125232 31SchmidtE.P.YangY.JanssenW.J.The" exact="pulmonary" post="endothelial glycocalyx regulates neutrophil adhesion and lung injury during"/>
 <result pre="and therapeutic target in sepsisCrit. Care23120191630654825 33LeeT.F.JantzieL.L.ToddK.G.CheungP.Y.Postresuscitation N-acetylcysteine treatment reduces" exact="cerebral" post="hydrogen peroxide in the hypoxic piglet brainIntensive Care Med.34200819019717938888"/>
 <result pre="J. Med.3291993200220127504210 35AkerstromS.Mousavi-JaziM.KlingstromJ.LeijonM.LundkvistA.MirazimiA.Nitric oxide inhibits the replication cycle of severe" exact="acute" post="respiratory syndrome coronavirusJ. Virol.7920051966196915650225 36CabralesP.TsaiA.G.FrangosJ.A.IntagliettaM.Role of endothelial nitric oxide"/>
 <result pre="Med.3291993200220127504210 35AkerstromS.Mousavi-JaziM.KlingstromJ.LeijonM.LundkvistA.MirazimiA.Nitric oxide inhibits the replication cycle of severe acute" exact="respiratory" post="syndrome coronavirusJ. Virol.7920051966196915650225 36CabralesP.TsaiA.G.FrangosJ.A.IntagliettaM.Role of endothelial nitric oxide in"/>
 <result pre="35AkerstromS.Mousavi-JaziM.KlingstromJ.LeijonM.LundkvistA.MirazimiA.Nitric oxide inhibits the replication cycle of severe acute respiratory" exact="syndrome" post="coronavirusJ. Virol.7920051966196915650225 36CabralesP.TsaiA.G.FrangosJ.A.IntagliettaM.Role of endothelial nitric oxide in microvascular"/>
 <result pre="and consumptionFree Radic. Biol. Med.39920051229123716214038 37RossaintR.FalkeK.J.LÃ³pezF.SlamaK.PisonU.ZapolW.M.Inhaled nitric oxide for the" exact="adult" post="respiratory distress syndromeN. Engl. J. Med.328619933994058357359 38ChenL.LiuP.GaoH.Inhalation of nitric"/>
 <result pre="consumptionFree Radic. Biol. Med.39920051229123716214038 37RossaintR.FalkeK.J.LÃ³pezF.SlamaK.PisonU.ZapolW.M.Inhaled nitric oxide for the adult" exact="respiratory" post="distress syndromeN. Engl. J. Med.328619933994058357359 38ChenL.LiuP.GaoH.Inhalation of nitric oxide"/>
 <result pre="Med.328619933994058357359 38ChenL.LiuP.GaoH.Inhalation of nitric oxide in the treatment of severe" exact="acute" post="respiratory syndrome: a rescue trial in BeijingClin. Infect. Dis.3920041531153515546092"/>
 <result pre="38ChenL.LiuP.GaoH.Inhalation of nitric oxide in the treatment of severe acute" exact="respiratory" post="syndrome: a rescue trial in BeijingClin. Infect. Dis.3920041531153515546092 39LeeH.Y.ZeeshanH.M.A.KimH.R.ChaeH.J.Nox4"/>
 <result pre="converting enzyme and angiotensin converting enzyme 2 in patients with" exact="chronic" post="heart failureJ. Renin-Angiotensin-Aldosterone Syst. JRAAS163201555355825869724 43ThatcherG.R.An introduction to NO-related"/>
 <result pre="enzyme and angiotensin converting enzyme 2 in patients with chronic" exact="heart" post="failureJ. Renin-Angiotensin-Aldosterone Syst. JRAAS163201555355825869724 43ThatcherG.R.An introduction to NO-related therapeutic"/>
 <result pre="experimental severe influenzaInt. J. Med. Sci.92201215716222253563 45AfshariA.BrokJ.MÃ¸llerA.M.WetterslevJ.Inhaled nitric oxide for" exact="acute" post="respiratory distress syndrome and acute lung injury in adults"/>
 <result pre="severe influenzaInt. J. Med. Sci.92201215716222253563 45AfshariA.BrokJ.MÃ¸llerA.M.WetterslevJ.Inhaled nitric oxide for acute" exact="respiratory" post="distress syndrome and acute lung injury in adults and"/>
 <result pre="J. Med. Sci.92201215716222253563 45AfshariA.BrokJ.MÃ¸llerA.M.WetterslevJ.Inhaled nitric oxide for acute respiratory distress" exact="syndrome" post="and acute lung injury in adults and children: a"/>
 <result pre="Sci.92201215716222253563 45AfshariA.BrokJ.MÃ¸llerA.M.WetterslevJ.Inhaled nitric oxide for acute respiratory distress syndrome and" exact="acute" post="lung injury in adults and children: a systematic review"/>
 <result pre="Analg.11220111411142121372277 46AdhikariN.K.J.BurnsK.E.A.FriedrichJ.O.GrantonJ.T.CookD.J.MeadeM.O.Effect of nitric oxide on oxygenation and mortality in" exact="acute" post="lung injury: systematic review and meta-analysisBMJ334200777917383982 47Al-Sa'doniH.H.FerroA.S-nitrosothiols as nitric"/>
 <result pre="and possible future therapeutic applicationsCurr. Med. Chem.112020042679269015544469 48KeyaertsE.VijgenL.ChenL.Inhibition of SARS-coronavirus" exact="infection" post="in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compoundInt."/>
 <result pre="Infect. Dis.84200422322615234326 49AkerstrÃ¶mS.GunalanV.KengC.T.TanY.J.MirazimiA.Dual effect of nitric oxide on SARS-CoV replication:" exact="viral" post="RNA production and palmitoylation of the S protein are"/>
 <result pre="Bio Mater.27201929072919 51NacharajuP.Tuckman-VernonC.MaierK.E.ChouakeJ.FriedmanA.CabralesP.FriedmanJ.M.A nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine: sustained" exact="vascular" post="responseNitric Oxide273201215016022705913 52Bellerophon Therapeutics announces first patient treated with"/>
 <result pre="Nrf2 and an antioxidant response and prevents hemin-induced toxicity in" exact="primary" post="cultures of cerebellar granule neurons of ratsOxid. Med. Cell."/>
 <result pre="of print, 2020 Jun 2] Abbreviations CoVs coronaviruses SARS severe" exact="acute" post="respiratory syndrome NO nitric oxide MERS Middle East respiratory"/>
 <result pre="print, 2020 Jun 2] Abbreviations CoVs coronaviruses SARS severe acute" exact="respiratory" post="syndrome NO nitric oxide MERS Middle East respiratory syndrome,"/>
 <result pre="2020 Jun 2] Abbreviations CoVs coronaviruses SARS severe acute respiratory" exact="syndrome" post="NO nitric oxide MERS Middle East respiratory syndrome, MERS"/>
 <result pre="severe acute respiratory syndrome NO nitric oxide MERS Middle East" exact="respiratory" post="syndrome, MERS COVID-19 coronavirus disease 2019 ARDS acute respiratory"/>
 <result pre="nitric oxide MERS Middle East respiratory syndrome, MERS COVID-19 coronavirus" exact="disease" post="2019 ARDS acute respiratory distress syndrome ALI acute lung"/>
 <result pre="Middle East respiratory syndrome, MERS COVID-19 coronavirus disease 2019 ARDS" exact="acute" post="respiratory distress syndrome ALI acute lung injury ACE2 angiotensin-converting"/>
 <result pre="East respiratory syndrome, MERS COVID-19 coronavirus disease 2019 ARDS acute" exact="respiratory" post="distress syndrome ALI acute lung injury ACE2 angiotensin-converting enzyme"/>
 <result pre="syndrome, MERS COVID-19 coronavirus disease 2019 ARDS acute respiratory distress" exact="syndrome" post="ALI acute lung injury ACE2 angiotensin-converting enzyme 2 NO/ROS"/>
 <result pre="COVID-19 coronavirus disease 2019 ARDS acute respiratory distress syndrome ALI" exact="acute" post="lung injury ACE2 angiotensin-converting enzyme 2 NO/ROS nitric oxide/reactive"/>
 <result pre="species RBC red blood cell IL interleukin IFN interferon TNF" exact="tumor" post="necrosis factor RAS renin angiotensin system S protein spike"/>
</results>
